StockTipsArenaBeta

SELL Lupin Limited — Citigroup

SELLLupin Limited

byCitigroupHorizon: NA (inferred 1 year)24 Aug 2026via Zee Business Stocks

Entry₹2,188Inferred
Target₹1,500
Total upside +31.44%
Stop lossNot given
CMP₹2,1102d ago
Active+3.56%+28.91%upside left 12 mo left
Follow Citigroup for new calls(100% target hit, 20 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 13 other Long-term calls on LUPIN

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 4:01 am IST
9 supporting2 neutral38 opposing
Supports the SELL call (9)

Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050

NewsEt-Markets·27 Aug · 1w ago

(opens in new tab)

Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive

NewsCnbc-Tv18·27 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (2)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 4w ago

(opens in new tab)
Weighs against the SELL call (38)

Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets

NewsCnbc-Tv18·4 Sept · 2d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Modafinil Tablets, USP.

BSE · Company Update·4 Sept · 2d ago

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Aug · 1w ago

9 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.